Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06681246
NA

The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment

Sponsor: Weizmann Institute of Science

View on ClinicalTrials.gov

Summary

This past century witnessed a significant increase in the prevalence of obesity. Successful weight loss maintenance is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping a low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications, including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. Antibiotics consumption is known to influence host glycemic response through changes induced in microbiome composition and function. Therefore, it may be a possible pathway to jumpstart changes in the gut microbiota. This study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered antibiotic treatment post-weight loss might be an effective intervention to prevent weight regain.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2024-12-11

Completion Date

2027-12

Last Updated

2026-01-20

Healthy Volunteers

Yes

Interventions

OTHER

Antibiotic treatment

10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day

OTHER

Placebo

consist of a combination of agarose in normal saline/glycerol

Locations (1)

Weizmann Institute of Science

Rehovot, Israel